<a ui-sref="about-us" ui-sref-active="active">
	<section class="jumbotron home">
		<div class="container">
			<h1>
				Innovative solutions<br>
				for carbohydrate<br>
				products and medicines.
			</h1>
			<p class="jumbo-click">Click here to find out more.</p>
			<div class="visible-sm visible-xs"></div>
		</div>
	</section>
</a>
<div class="container">
	<div class="row">
		<div class="col-sm-6">
			<h3 class="news-header">
			News
			</h3>
			<ul class="news-partner">
				<li>
				<strong>Sept. 2016</strong> - Glycan Therapeutics has added 32 new compounds to its catalog. Each new compound has an Azido functional group that can be used to couple with a flourescent or affinty tag. These new compounds are only available through <a ng-href="/products/compounds?tag=Az">Glycan Therapeutics</a>.
				</li><br>
				<li>
				<strong>Oct. 2015</strong> - Glycan Therapeutics has been awarded a SBIR phase II contract from National Institute of Cancer
				with a total budget of close to $1 million over two years. The contract has commissioned the 
				company to synthesize a library of heparan sulfate oligosaccharides for cancer-related research.
				</li>
			</ul>
		</div>
		<div class="col-sm-6">
			<h3 class="news-header">
			Partnerships & Investment Opportunities
			</h3>
			<p class="news-partner">
				We welcome inquiries about partnerships and/or investment into research and development of 
				synthetic carbohydrate therapeutics. Feel free to contact us at <a href="mailto:info@glycantherapeutics.com" target="_top">info@glycantherapeutics.com</a>
			</p>
		</div>
	</div>
</div>